In addition, we can exclude here a potential immunomodulatory effect of anti-thyroid drugs in Group 2 patients (36) because (1) some GD group 1 patients that are efficiently treated with anti-thyroid drugs, i.e., they are euthyroid, display an increased prevalence of TLS and GCs with increased CXCR5+ FOXP3+ Tfr, LTi-like ILC3, and CXCR5+ PD-1hi CD4+ Tfh cells and (2) some group 2 patients are still displaying hyperthyroidism without infiltrates while under treatment (Table S1). This evidence concerns the gene TFRC and hyperthyroidism.